"We don't work for consumers in Argentina or Africa, and we don't care about public health issues there." That was how the US deputy assistant trade representative for intellectual property responded two years ago to a suggestion that the US trade representative (USTR) should approach pharmaceutical patent policies as a public health issue rather than as a trade issue.